STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Corp. - GERN STOCK NEWS

Welcome to our dedicated news page for Geron (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geron's position in the market.

News
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
Rhea-AI Summary
Geron Corporation's Marketing Authorization Application (MAA) for imetelstat has been validated by the European Medicines Agency (EMA), bringing them closer to potentially offering the treatment to lower risk MDS patients in the EU. Clinical results have shown significant efficacy, with higher transfusion independence rates and increased hemoglobin levels in imetelstat-treated patients compared to placebo. The MAA is now under regulatory review and expected to take approximately 14 months. The company is also awaiting a decision from the U.S. FDA with a PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
News
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
Rhea-AI Summary
Geron Corporation appoints Michelle Robertson as CFO and Treasurer, effective September 25, 2023. Olivia Bloom retires after 30 years with the company. Robertson brings over 30 years of financial experience. Inducement grants of 1.6 million shares of Geron common stock planned for Robertson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
management
-
News
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
Rhea-AI Summary
Geron announces positive data from IMerge Phase 3 trial for imetelstat in lower risk MDS, with significant increases in transfusion independence and hemoglobin levels, improvement in fatigue, and manageable safety profile. New Drug Application for imetelstat accepted for review by FDA with PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition clinical trial
News
Geron to Participate in the Baird 2023 Global Healthcare Conference
Rhea-AI Summary
Geron CEO to participate in fireside chat at Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
News
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
Rhea-AI Summary
Geron Corporation announced FDA review and PDUFA action date of June 16, 2024 for imetelstat NDA. Expecting US launch by H1 2024, subject to FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.31%
Tags
none
-
News
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
Rhea-AI Summary
Geron's NDA for imetelstat accepted by FDA for the treatment of anemia in MDS patients. Positive efficacy results and significant increase in hemoglobin levels. Expectation of changing standard of care in lower risk MDS. Safety consistent with prior clinical experience. FDA has up to 74 days to notify PDUFA action date. MAA submission in EU expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
clinical trial
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron Corporation has granted non-statutory stock options to newly hired employees, totaling 189,850 shares. The options were granted at an exercise price of $2.70 per share and have a 10-year term. Some options vest over four years, while others vest upon achievement of a regulatory milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
earnings
-
News
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
earnings
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
Stock GERN logo
Geron Corp.

Nasdaq:GERN

GERN Rankings

#1788 Ranked by Market Cap
#3292 Ranked by Stock Gains
N/A Ranked by Dividends

GERN Stock Data

2.14B
475.07M
0.09%
67.83%
7.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Foster City

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.